Anbio Biotechnology, a global medical technology and in vitro diagnostics firm, priced its initial public offering (IPO) of 1,600,000 Class A ordinary shares at US$5.00 per share. These shares are slated for listing on the Nasdaq Global Market, commencing trading on February 19, 2025, under the ticker symbol “NNNN.”

The company anticipates gross proceeds of US$8 million from the offering, before accounting for underwriting discounts and expenses. The offering is projected to close around February 20, 2025, contingent on standard closing conditions.

Funds raised will be allocated to expanding sales and distribution networks in key markets, research and development initiatives, and general corporate purposes, including working capital.

AC Sunshine Securities LLC is the underwriter for this firm commitment offering. Ortoli Rosenstadt LLP serves as U.S. counsel for Anbio, while Focus Law represents the underwriter.

The SEC declared effective the registration statement (Form F-1, File Number: 333-284106) on February 18, 2025. The offering is exclusively through a prospectus, part of the registration statement. Prospectuses are available from AC Sunshine Securities LLC via email at , mail to 200 E. Robinson Street, Suite 295, Orlando, FL 32801, or by phone at +1 (689)-689-9686, and on the SEC website at .

Investors should review the prospectus and SEC filings before investing. This press release is not an offer to sell or solicitation to buy securities, and sales are subject to registration or exemption requirements. No sales will occur where prohibited by law.

About Anbio Biotechnology

Anbio Biotechnology is a global diagnostics company focused on advancing medical technology and supplying in vitro diagnostics (IVD) products. Its portfolio includes various diagnostic assays and five biomarker detection platforms: Fluorescent Immunochromatographic Solution (FIA), Chemiluminescent Immunoassay Solution (ChLIA), Polymerase Chain Reaction Solution (PCR), Lateral Flow Assay Solution (LFIA), and Loop-Mediated Isothermal Amplification Solution (LAMP). These solutions serve point-of-care, laboratory, and over-the-counter needs, providing fast, reliable, and affordable diagnostics. With a global presence and CE-marked products, Anbio addresses various medical areas including infectious diseases, cancer, and more, using diverse sample types. Anbio prioritizes innovation, affordability, and speed to transform global diagnostics.

Forward-Looking Statements

This announcement contains forward-looking statements, including regarding the offering. These statements involve risks and uncertainties and are based on current expectations. Words like “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” and similar expressions often identify forward-looking statements. The company is not obligated to update these statements, except as legally required. While the company believes these statements are reasonable, actual results may differ materially. Investors should review the registration statement and other SEC filings for more information.

For more information, please contact: